When TDP-43 escapes from the nucleus, cells bungle mRNA processing, chopping up and splicing transcripts in the wrong places. Most studies have focused on retention of “cryptic” exons, but recent work ...
Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) is a transmembrane receptor found on microglia, where it modulates cell activity and survival. In addition to membrane-associated TREM2, there ...
Phosphorylated tau isn’t just pathological junk; it helps the brain defend against viral infections. So claim scientists led by Rudolph Tanzi and William Eimer at Massachusetts General Hospital in ...
Inflammation is known to contribute to Alzheimer’s disease progression, fueling the buildup of tau and amyloid pathology, and yet epidemiology suggests that people with the chronic inflammatory ...
A documentary of country legend Glen Campbell's life and “Goodbye Tour” following his diagnosis of Alzheimer's.
A single-center pilot study at the Veterans Affairs Hospital/University of Washington in Seattle reported improved verbal memory retention and attention after a three-week test of 20 international ...
Funding ($5,000 to $20,000) is for UMN NSC core use only.
The center currently accepts only fresh brain donations from the general population, and does not bank Alzheimer's brains or brains with unspecified dementia. Normal controls are welcome, as are ...
Perlman Neurology Outpatient Clinic 8950 Villa La Jolla Drive Suite C129 La Jolla, CA92037 United States Visit Website Contact: Douglas Galasko, M.D Phone: 858-657-8540 E-mail: [email protected] ...
The dbl-PAC-Tg(SNCA A53T) +/+;Snca-/-model, referred to here as double-transgenic mice, are mice lacking endogenous α-synuclein (Snca knockout mice) that were crossed with two homozygous transgenic ...
Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...
Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...